The role of zinc in Alzheimer’s disease (AD) is a much debated topic and the potential of zinc as an AD biomarker has come under scrutiny in recent years. Now scientists in Australia have added to evidence that no change in serum zinc concentration is seen in AD, and that decreasing zinc levels are instead a sign of ageing.
AD, the most common form of dementia, affects millions of people worldwide, and with limited treatments available, much effort is being devoted towards new therapies and early diagnosis. The identification of AD biomarkers in the blood is an attractive goal for researchers developing new diagnostic tools, and given its potential implications in the disease, zinc appeared to be a good candidate. However, conflicting studies appear in the literature, with significance increases, decreases, as well as no significant changes, all being reported.
To read the full article by Kirsty Muirhead, please visit Chemistry World
Decreased serum zinc is an effect of ageing and not Alzheimer’s disease
Alan Rembach, Dominic J. Hare, James D. Doecke, Samantha C. Burnham, Irene Volitakis, Christopher J. Fowler, Robert A. Cherny, Catriona McLean, Rudolf Grimm, Ralph Martins, David Ames, Colin L. Masters, Ashley I. Bush and Blaine R. Roberts
Metallomics, 2014, Advance Article
DOI: 10.1039/C4MT00060A, Communication